Business Wire

Xpansiv Announces Acquisition of Evident to Strengthen Global Renewable Energy Markets

3.11.2025 08:00:00 CET | Business Wire | Press Release

Share

Xpansiv® Limited (“Xpansiv”) and Evident Group Limited (“Evident”) today announced an agreement uniting their complementary registry and infrastructure capabilities to support the continued growth of the global renewable energy markets.

The agreement, in which Xpansiv has wholly acquired Evident, follows an earlier, minority investment by Xpansiv in the registry operator and certification body. It combines Evident's international renewable energy for electricity “I-REC(E)” and other registries with Xpansiv’s North American Renewables Registry (NAR™) and Tradable Instrument for Global Renewables Registry (TIGR™) to establish a preeminent, global REC network with over 300 GW of capacity and more than 4,000 participating companies.

“Today’s announcement reflects the shared goals and close relationship we have developed with Evident as we work to build energy transition solutions at scale, centering on transparent, independent certification and robust infrastructure,” said John Melby, CEO, Xpansiv. “It is also a milestone in our diversification strategy to build out our renewable energy and power markets portfolio to more fully support the global energy transition. Along with our exchange, market execution, and portfolio integration capabilities, we’re making it easier than ever for companies to transact clean energy certificates and meet their sustainability goals.”

Evident’s role as an independent certification body and its governance under the I-TRACK Foundation remain unchanged. Evident will continue to operate as an independent market facilitator for I-REC(E) and other products, under the ongoing oversight of the I-TRACK Foundation and in alignment with the International Attribute Tracking Standard. This governance structure ensures the highest levels of transparency and market integrity.

“The I-TRACK Foundation is looking forward to continuing to support Evident, as an Accredited Code Manager under the I-TRACK Foundation's International Attribute Tracking Standard, as it grows its impact, reach, and innovation across vital and trustworthy EAC markets,” said Dirk Van Evercooren, Chairman of the Board, I-TRACK Foundation.

Users of Evident’s infrastructure can remain confident that the robustness, quality, and reliability of its services will not only be maintained but enhanced. The acquisition will serve as a platform for even greater innovation and continued advancement within the global REC registry sector.

"Through the talent and expertise of our fantastic team, Evident has become the pre-eminent trusted partner for sustainable energy certification across more than 60 countries,” said Ed Everson, Co-Founder, Evident. “Thank you to all those within Evident who have made that success possible."

The acquisition comes as global demand for renewable energy and RECs is growing sharply, driven by electricity consumption by data centers, electric vehicles, and other sources. The International Energy Agency (IEA) projects global renewable electricity capacity will double by 2030, adding 4,600 GW, equal to the combined installed power capacity of China, the European Union, and Japan.

This year, more than 300 million I-REC(E)s were issued by Evident through September, up from 2024’s 290 million full-year total. Since 2015, Evident has grown from supporting a single market to more than 60 countries, serving over 95% of the voluntary renewable energy certificate market outside Europe and North America. In September, the company issued its one billionth I-REC(E). Evident also operates registries for methane emission reduction and sustainable aviation fuel.

“The acquisition of Evident, a premier global registry provider in the fast-growing renewable energy markets, underscores our strategy to expand our comprehensive platform through acquisitions and organic growth,” said Nathan Rockliff, Chief Strategy Officer, Xpansiv.

Xpansiv’s renewable energy network, which also includes leading U.S. compliance registries MIRECS, NC-RETS, NEPOOL, and NYGATS, is integrated via the Xpansiv® Connect™ multi-registry portfolio management system and CBL® spot exchange. With full issuance-to-retirement lifecycle support, participants can manage positions efficiently and trade more confidently.

Marlborough Partners, Deloitte, Clifford Chance, and Ashurst served as advisors to Xpansiv.

For more information, please visit www.xpansiv.com and https://evident.global/.

View source version on businesswire.com: https://www.businesswire.com/news/home/20251102941424/en/

Contacts

Media contact:pr@xpansiv.com

(c) 2024 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:19:00 CEST | Press Release

Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com

BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press Release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta

inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press Release

inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and

Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press Release

Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by up to 97% within two months, TP53 and KRAS mutations near undetectable. Immune activity (first six patients): STC-1010 regimen nearly quadrupled cytotoxi

Takeda Announces Arcotatug Tavatecan (TAK-921) Demonstrated Statistically Significant and Clinically Meaningful Improvements in Overall Survival and Progression-Free Survival in Phase 3 Advanced Gastric Cancer Study23.10.2026 13:30:00 CEST | Press Release

Takeda(TSE:4502/NYSE:TAK)announced positive results from the Phase 3 G-HOPE-001 study (NCT06238843) of arcotatug tavatecan (TAK-921; Innovent R&D code: IBI343) in patients with Claudin (CLDN)18.2-positive, previously treated, advanced gastric or gastroesophageal junction adenocarcinoma (G/GEJA). Results from two prespecified interim analyses, which were shared in a late-breaking oral presentation at the 2026 European Society for Medical Oncology (ESMO) Congress, showed the study met its dual primary endpoints of overall survival (OS) and progression-free survival (PFS). Gastric cancer is a leading cause of cancer-related death worldwide, and outcomes are particularly poor once the disease is advanced.1 Because treatment options are limited for people whose cancer continues to progress after multiple therapies, there is a significant need for new targeted therapies.2 CLDN18.2, a protein found at abnormally high levels on the surface of certain cancer cells, has emerged as a key biomarke

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye